CompanyPrivateParis

Biophytis SA

Biophytis develops BIO101, a small molecule for sarcopenia and obesity.

SEC EDGAR ClinicalTrials.gov

6-KNov 9Latest SEC filing

Form DSep 23$2.6M sold

November 2026

Biophytis reports H1 2026 results, advances BIO101 obesity and sarcopenia plans

Nov 2Quarterly updateBiophytis SA